CALGARY, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- Bonterra Energy Corp. (TSX: BNE; OTCID: BNEFF) (“Bonterra” or the “Company”) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2025, achieving a record annual production, together with highlights of an independent oil and gas reserves evaluation (the “Sproule Report”) prepared by Sproul...
CALGARY, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- Bonterra Energy Corp. (TSX: BNE; OTCID: BNEFF) (“Bonterra” or the “Company”) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2025, achieving a record annual production, together with highlights of an independent oil and gas reserves evaluation (the “Sproule Report”) prepared by Sproule International Limited (“Sproule”), effective December 31, 2025. The related financial statements and notes, as well as management’s discussion and analysis along with the annual information form for the period ended December 31, 2025, are available on SEDAR+ www.sedarplus.ca and on our website www.bonterraenergy.com. Record annual production of 15,513 BOE per day , exceeding revised guidance and representing a 5% increase from the prior year , exceeding revised guidance and representing a 5% increase from the prior year Expanded Charlie Lake core area through the closing of the previously announced Bonanza asset acquisition, consisting of low-decline oil pools producing approximately 760 BOE per day (3) and 21 top-tier drilling locations through the closing of the previously announced Bonanza asset acquisition, consisting of low-decline oil pools producing approximately 760 BOE per day and 21 top-tier drilling locations Achieved reserves growth across Total Proved (“TP”) and Total Proved Plus Probable (“TPP”) reserve categories of 3%, underpinning TPP Reserve Life Index of 19.4 years; Reduced TP and TPP F&D costs (2) to $12.72/BOE and $14.93/BOE driving recycle ratios (2) of 2.1x and 1.8x, respectively across Total Proved (“TP”) and Total Proved Plus Probable (“TPP”) reserve categories of 3%, underpinning TPP Reserve Life Index of 19.4 years; Reduced TP and TPP F&D costs to $12.72/BOE and $14.93/BOE driving recycle ratios of 2.1x and 1.8x, respectively Capital spending of $69.9 million , in line with guidance , in line with guidance Adjusted Free Funds Flow (1) of $17.2 m...
Galeanu Mihai/iStock via Getty Images The following segment was excerpted from the Royce Smaller-Companies Growth Fund FY 2025 Commentary. Nine of the portfolio’s 10 equity sectors made a positive impact on calendar year performance, with Health Care, Industrials, and Materials making the largest positive contributions while the only negative impact came from Consumer Staples. At the industry leve...
Galeanu Mihai/iStock via Getty Images The following segment was excerpted from the Royce Smaller-Companies Growth Fund FY 2025 Commentary. Nine of the portfolio’s 10 equity sectors made a positive impact on calendar year performance, with Health Care, Industrials, and Materials making the largest positive contributions while the only negative impact came from Consumer Staples. At the industry level, health care providers & services (Health Care), aerospace & defense (Industrials), and pharmaceuticals (Health Care) contributed most, while software (Information Technology), commercial services & supplies (Industrials), and food products (Consumer Staples) were the largest detractors. Our top-contributing position was Palvella Therapeutics (PTX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN platform—a proprietary technology that focuses on delivering highly targeted technologies directly to the disease source. Palvella’s shares appreciated significantly in 2025 as investors grew more confident in the company’s pipeline following a grant from the FDA, patent wins, expanded indications and programs, and a positive Phase II readout, with an additional Phase III readout expected in 1Q26. QTORIN rapamycin has the potential to be the only approved therapy in multiple rare disease settings, supporting a potential $2 billion+ commercial opportunity. Palvella has recently expanded its pipeline to address additional opportunities across rare skin diseases. We began building a position in February of 2025, when it was a mostly undiscovered, and uncovered, company, with just a few sell side analysts covering the stock; today, there are 15. Hims & Hers Health ( HIMS ) operates a telehealth consultation platform that provide...
Senate Republicans On Iran War Ending: Sooner The Better The ongoing U.S. military operation against Iran, which began February 28th with strikes aimed at destroying Iran's nuclear program, ballistic missile capabilities, navy, and other strategic assets, has prompted a range of reactions from Republican senators . While most GOP lawmakers initially supported President Trump's actions - evidenced ...
Senate Republicans On Iran War Ending: Sooner The Better The ongoing U.S. military operation against Iran, which began February 28th with strikes aimed at destroying Iran's nuclear program, ballistic missile capabilities, navy, and other strategic assets, has prompted a range of reactions from Republican senators . While most GOP lawmakers initially supported President Trump's actions - evidenced by the Senate's largely party-line vote on March 4th to block a bipartisan war powers resolution that would have curtailed or required congressional approval for the conflict - several prominent voices have emphasized the need for a swift conclusion rather than a prolonged engagement. Senator Josh Hawley (R-MO) , a key Trump ally, became one of the most vocal advocates for an early exit during his appearance on Jesse Watters Primetime on Tuesday. Hawley urged the president to "declare victory" and withdraw U.S. forces, arguing that core objectives have already been met. Watters: Do you think the President is going to look for an off-ramp or keep going? Hawley: I think he [Trump] has achieved his objectives the way that he’s laid them out… What is there, really, that’s left to do that we haven’t already done? … We have totally destroyed, forever, their nuclear program. We have destroyed their ballistic missiles. We have destroyed their navy. This has been a total success… I think we ought to say to our heroes, ‘Thank you for a job well done.’ This has been absolutely amazing. It’s been amazing. It’s been historic. And now it’s time to declare victory. Watch: Hawley on Iran: What is there really that's left to do that we haven't already done? It's time to declare victory. pic.twitter.com/fSM2yFvMZ0 — Acyn (@Acyn) March 11, 2026 This positioned Hawley as the first prominent Trump-aligned senator to publicly push for an end in this manner. Senator Rand Paul (R-Ky.) , known for his non-interventionist stance, has been the other GOP senator openly critical or unsupportive - oppos...
President Donald Trump and Iran’s new supreme leader both struck defiant tones on the 13th day of the war, offering little relief to energy markets despite fresh US efforts to curb oil prices. Bloomberg's Derek Wallbank breaks down the latest developments. (Source: Bloomberg)
President Donald Trump and Iran’s new supreme leader both struck defiant tones on the 13th day of the war, offering little relief to energy markets despite fresh US efforts to curb oil prices. Bloomberg's Derek Wallbank breaks down the latest developments. (Source: Bloomberg)
Inflows into leveraged exchange-traded funds and elevated levels of borrowed cash to buy stocks are reviving fears that some of Asia’s largest markets may suffer a repeat of last week’s war-induced selloff. Leveraged ETFs in the region received net inflows over both the past week and month, according to data compiled by Bloomberg. In China , Taiwan and South Korea , the amounts of margin loans sat...
Inflows into leveraged exchange-traded funds and elevated levels of borrowed cash to buy stocks are reviving fears that some of Asia’s largest markets may suffer a repeat of last week’s war-induced selloff. Leveraged ETFs in the region received net inflows over both the past week and month, according to data compiled by Bloomberg. In China , Taiwan and South Korea , the amounts of margin loans sat near the highest in decades, with Japan ’s at a record, data as of the end of last week show. The persistently strong appetite for leveraged bets is a sign that there remains plenty of froth in the market, with dip-buyers looking to maximize potential gains in case the Iran war ends soon. The Asian markets look particularly vulnerable to the prospect of a prolonged conflict and resurgent oil prices, given their much worse performance than Wall Street last week. “There is still potential for levered investors and crowded positions to be flushed out if volatility remains elevated,” said Nick Ferres , chief investment officer of Vantage Point Asset Management in Singapore. Read more: Decade-High Margin Levels in Asia Help Explain Selling Intensity Ferres, who runs an Asia-focused global macro fund, said heightened leverage is a factor that has made him stay on the sidelines since the war began, amid concerns about another stock rout. In the five trading sessions through Thursday, Asia-listed leveraged ETFs that amplify returns across equity, fixed income and commodity strategies had attracted $4.5 billion in net inflows. NEXT FUNDS Nikkei 225 Leveraged Index ETF $1.4 billion CSOP SK Hynix Daily 2x Leveraged Product $782.2 million Samsung KODEX Leverage ETF Equity-Derivatives FoF $642.8 million Samsung Kodex KOSDAQ150 Leverage ETF $509.9 million CSOP Samsung Electronics Daily 2x Leveraged Product $324.4 million Japan-listed NEXT FUNDS Nikkei 225 Leveraged Index ETF attracted $1.4 billion during the period, the largest haul across the region. Single-stock leveraged funds also d...
Image source: The Motley Fool. Thursday, March 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Linda Marbán Chief Financial Officer — Anthony J. Bergmann Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS BLA Review Timeline -- The FDA accepted Capricor Therapeutics CAPR 0.45% ) -- The FDA accepted Clinical Trial Data -- The pivotal HOPE-3 Phase 3 trial...
Image source: The Motley Fool. Thursday, March 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Linda Marbán Chief Financial Officer — Anthony J. Bergmann Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS BLA Review Timeline -- The FDA accepted Capricor Therapeutics CAPR 0.45% ) -- The FDA accepted Clinical Trial Data -- The pivotal HOPE-3 Phase 3 trial met its primary endpoint (Performance of the Upper Limb) and all Type 1 error-controlled secondary endpoints, with left ventricular ejection fraction showing a 91% reduction in disease progression among all evaluable patients and achieving statistical significance. -- The pivotal HOPE-3 Phase 3 trial met its primary endpoint (Performance of the Upper Limb) and all Type 1 error-controlled secondary endpoints, with left ventricular ejection fraction showing a 91% reduction in disease progression among all evaluable patients and achieving statistical significance. Subgroup Results -- Among HOPE-3 participants with cardiomyopathy, the left ventricular ejection fraction endpoint achieved a p-value of 0.01. -- Among HOPE-3 participants with cardiomyopathy, the left ventricular ejection fraction endpoint achieved a p-value of 0.01. Duchenne Video Assessment (DVA) -- The trial showed statistically significant improvement in upper limb function, as measured by home-based DVA EAT 10 BITE, with approximately 50 treated and 50 placebo patients in the analysis. -- The trial showed statistically significant improvement in upper limb function, as measured by home-based DVA EAT 10 BITE, with approximately 50 treated and 50 placebo patients in the analysis. Cardiac Fibrosis Data -- Cardiac MRI with gadolinium demonstrated a significant reduction in fibrosis in deramycin-treated patients compared to placebo; this was measured in Cohort B only. -- Cardiac MRI with gadolinium demonstrated a significant reduction in fibrosis in deramycin-treated patients compared to placebo; this was measured ...
Backed by Jeff Bezos, Slate Auto is looking to disrupt the electric vehicle marketplace with a basic pickup truck for less than $30,000. The company has yet to release a product and is already making a switch at the CEO role. Here's who will lead the company going forward. Slate Auto Names New CEO Slate Auto has raised $700 million in funding, with Amazon founder Bezos among the largest backers. W...
Backed by Jeff Bezos, Slate Auto is looking to disrupt the electric vehicle marketplace with a basic pickup truck for less than $30,000. The company has yet to release a product and is already making a switch at the CEO role. Here's who will lead the company going forward. Slate Auto Names New CEO Slate Auto has raised $700 million in funding, with Amazon founder Bezos among the largest backers. While Bezos isn't involved in the day-to-day operations, Slate is turning to another former Amazon executive to help. Slate announced that Peter Faricy is the new CEO, succeeding former CEO Christine Barman, as reported by TechCrunch. Barman, who served as the company's first CEO, is moving to the role of president of Vehicles. Don't Miss: Faricy comes to Slate Auto from McKinsey and Bessemer Venture Partners, where he was an adviser. Before his time there, Faricy previously spent 12 years with Amazon from 2006 to 2018, where nine of the years were spent as the vice president of Amazon Marketplace. According to Faricy's LinkedIn profile, he also spent time at Ford Motor Co from 1999 to 2002 as an executive director. "Peter's experience building Amazon Marketplace was really critical for us," Slate spokesperson Jeff Jablansky told TechCrunch. Along with the new CEO, previously working at Amazon and Bezos' backing, Slate has close connections to Amazon, with former Amazon executive Diego Piacentini also an investor in the company. Slate co-founder Jeff Wilke also previously served as the Amazon Consumer CEO. Members in Slate's mobility, commerce, fleet sales and HR teams also had previous roles at Amazon. Trending: Disney Was Built on Character IP — This Pre-IPO Company Is Using the Same Playbook What's Next for Slate The CEO change comes ahead of Slate's launch of its electric pickup truck, which has over 160,000 reservations according to the report. That's up from 150,000 in December. The company's goal is to begin deliveries of the truck later this year. Slate previously sa...
(RTTNews) - The Taiwan stock market on Thursday snapped the two-day winning streak in which it had surged more than 2,000 points or 6 percent. The Taiwan Stock Exchange now sits just above the 33,580-point plateau and it's likely to see more profit taking on Friday. The global forecast for the Asian markets remains negative on surging oil prices and raging war in the Middle East. The European and ...
(RTTNews) - The Taiwan stock market on Thursday snapped the two-day winning streak in which it had surged more than 2,000 points or 6 percent. The Taiwan Stock Exchange now sits just above the 33,580-point plateau and it's likely to see more profit taking on Friday. The global forecast for the Asian markets remains negative on surging oil prices and raging war in the Middle East. The European and U.S. markets were down and the Asian bourses are expected to follow suit. The TSE finished sharply lower on Thursday following losses from the technology and plastics companies, while the financial sector came in mixed. For the day, the index plunged 532.33 points or 1.56 percent to finish at 33,581.86 after trading between 33,458.64 and 34,019.48. Among the actives, Mega Financial slumped 1.27 percent, while CTBC Financial perked 0.16 percent, First Financial skidded 1.03 percent, Fubon Financial collected 0.22 percent, E Sun Financial sank 0.75 percent, Taiwan Semiconductor Manufacturing Company stumbled 2.84 percent, United Microelectronics Corporation surrendered 2.57 percent, Hon Hai Precision dropped 2.05 percent, Largan Precision retreated 1.46 percent, Catcher Technology spiked 2.75 percent, MediaTek climbed 1.13 percent, Delta Electronics tanked 2.14 percent, Novatek Microelectronics rose 0.26 percent, Formosa Plastics tumbled 1.91 percent, Nan Ya Plastics plummeted 5.95 percent, Asia Cement rallied 2.21 percent and Cathay Financial was unchanged. The lead from Wall Street is weak as the major averages opened firmly in the red and remained under water throughout the session, ending at daily lows. The Dow tumbled 739.42 points or 1.56 percent to finish at 46,677.85, while the NASDAQ plunged 404.15 points or 1.78 percent to end at 22,311.98 and the S&P 500 slumped 103.18 points or 1.52 percent to close at 6,672.62. The sell-off on Wall Street came amid another sharp increase by the price of crude oil, as oil prices further offset the nosedive seen on Tuesday. Crude o...